Rasonque EU Approval: Daraxonrasib Becomes Europe’s First RAS Pill for Pancreatic Cancer
The European Commission has approved Revolution Medicines’ Rasonque (daraxonrasib) for previously treated metastatic pancreatic cancer, with or without a RAS mutation. Here is what the label covers and when patients may get it.
